Two randomized, double-blind studies demonstrated that a new antipsychotic treatment for adult patients with schizophrenia may lead to a meaningful reduction in symptoms.
The FDA Psychopharmacologic Drug Advisory Committee and Drug Safety and Risk Management Advisory Committee jointly voted on the benefit-risk profile of esketamine nasal spray for the treatment of adults...
The US Food and Drug Administration has approved a shortened version of existing brain stimulation protocol for treatment-resistant major depressive disorder.
Aristada recently received approval from the US Food and Drug Administration for a new and shorter dosing regimen, providing more options to patients and health care providers.
